#non-opioid painkiller

Non-Opioid Painkiller Developer Latigo Edges Higher After IPO

Shares of non-opioid painkiller maker Latigo rose modestly after its upsized IPO, signaling investor interest in the biotech's pain management solutions.

Latigo Prices IPO at $345.6 Million, Debuts as Non-Opioid Pain Drug Developer

Latigo's $345.6 million IPO highlights Wall Street's bet on non-opioid pain therapies, marking a significant entry for the biotech firm into public…

Latigo Biotech Files for $288M Nasdaq IPO to Fund Non-Opioid Pain Drugs

Latigo files for $288M US IPO to advance its non-opioid painkiller pipeline, capitalizing on strong investor interest in safer alternatives to addictive…